A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides

References

• Aderka D. (1991). Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis: potential new therapeutic implications. Isr J Med Sci 27:52–60.
   PubMedGoogle Scholar
• Aguillon JC, Ferreira V, Nunez E, et al. (1996). Immunomodulation of LPS ability to induce the local Shwartzman reaction. Scand J Immunol 44:551–5.
   PubMed Web of Science ®Google Scholar
• Ali ME, Lamprecht A. (2013). Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation. Int J Pharm 456:135–42.
   PubMed Web of Science ®Google Scholar
• Allhenn D, Neumann D, Béduneau A, et al. (2013). A ‘drug cocktail’ delivered by microspheres for the local treatment of rat glioblastoma. J Microencapsul 30:667–73.
   PubMed Web of Science ®Google Scholar
• Ando T, Ito H, Arioka Y, et al. (2015). Combination therapy with α-galactosylceramide and a Toll-like receptor agonist exerts an augmented suppressive effect on lung tumor metastasis in a mouse model. Oncol Rep 33:826–32.
   PubMed Web of Science ®Google Scholar
• Aurell CA, Wistrom AO. (1998). Critical aggregation concentrations of gram-negative bacterial lipopolysaccharides (LPS). Biochem Biophys Res Commun 253:119–23.
   PubMed Web of Science ®Google Scholar
• Awasthi S. (2014). Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol 5: 328.
   PubMed Web of Science ®Google Scholar
• Barratt GM, Raddassi K, Petit JF, et al. (1991). MDP and LPS act synergistically to induce arginine-dependent cytostatic activity in rat alveolar macrophages. Int J Immunopharmacol 13:159–65.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21:687–92.
   PubMed Web of Science ®Google Scholar
• Beletskii A, Galloway A, Rele S, et al. (2014). Engineered PRINT® nanoparticles for controlled delivery of antigens and immunostimulants. Hum Vaccin Immunother 10:1908–13.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Dalgleish AG, Carmichael J, et al. (2000). Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6:397–405.
   PubMed Web of Science ®Google Scholar
• Bronte V, Pittet MJ. (2013). The spleen in local and systemic regulation of immunity. Immunity 39:806–18.
   PubMed Web of Science ®Google Scholar
• Chicoine MR, Won EK, Zahner MC. (2001). Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery 48:607–14. discussion 614–615.
   PubMed Web of Science ®Google Scholar
• Demento SL, Eisenbarth SC, Foellmer HG, et al. (2009). Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27:3013–21.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. (2007). Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469–78.
   PubMed Web of Science ®Google Scholar
• Engelhardt R, Mackensen A, Galanos C. (1991). Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51:2524–30.
   PubMed Web of Science ®Google Scholar
• Garay RP, Viens P, Bauer J, et al. (2007). Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharm 563:1–17.
   PubMed Web of Science ®Google Scholar
• Gómez S, Gamazo C, San Roman B, et al. (2008). Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. Eur J Pharm Biopharm 70:711–7.
   PubMed Web of Science ®Google Scholar
• Goto S, Sakai S, Kera J, et al. (1996). Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42:255–61.
   PubMed Web of Science ®Google Scholar
• Heckelsmiller K, Rall K, Beck S, et al. (2002). Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169:3892–9.
   PubMed Web of Science ®Google Scholar
• Heinz H, Pramanik C, Heinz O, et al. (2017). Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications. Surf Sci Rep 72:1–58.
   Web of Science ®Google Scholar
• Held TK, Weihua X, Yuan L, et al. (1999). Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infect Immun 67:206–12.
   PubMed Web of Science ®Google Scholar
• Hjort PF, Rapaport SI. (1965). The Shwartzman reaction: pathogenetic mechanisms and clinical manifestations. Annu Rev Med 16:135–68.
   PubMed Web of Science ®Google Scholar
• Isambert N, Fumoleau P, Paul C, et al. (2013). Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 13:172.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kirikae T, Hirata M, et al. (1991). Local skin response in mice induced by a single intradermal injection of bacterial lipopolysaccharide and lipid A. Infect Immun 59:1954–60.
   PubMed Web of Science ®Google Scholar
• Jiao Q, Li L, Mu Q, et al. (2014). Immunomodulation of nanoparticles in nanomedicine applications. Biomed Res Int 2014, Article ID 426028, 19 pages.
   Web of Science ®Google Scholar
• Lamprecht A, Bouligand Y, Benoit JP. (2002). New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Release 84:59–68.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen K, Wang C, et al. (2013). Isolation of mice tumor-infiltrating leukocytes by percoll gradient centrifugation. Bio-Protocol 3:e892–6.
   Google Scholar
• MacEwan SR, Callahan DJ, Chilkoti A. (2010). Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond) 5:793–806.
   PubMed Web of Science ®Google Scholar
• Madonna G, Peterson J, Ribi E, et al. (1986). Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. In Fect Immun 18:107–12.
   Google Scholar
• Maggio ET. (2012). Polysorbates, peroxides, protein aggregation, and immunogenicity – a growing concern. J Exp Food Chem 3:45–53.
   Google Scholar
• Matzner P, Sorski L, Shaashua L, et al. (2016). Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int J Cancer 138:1754–64.
   PubMed Web of Science ®Google Scholar
• McAleer JP, Vella AT. (2008). Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol 28:281–99.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. (2011). Cancer immunotherapy comes of age. Nature 480:480–9.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge EM, Liversidge GG. (2008). Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36:43–8.
   PubMed Web of Science ®Google Scholar
• Mottram PL, Leong D, Crimeen-Irwin B, et al. (2007). Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 4:73–84.
   PubMed Web of Science ®Google Scholar
• Mundargi RC, Babu VR, Rangaswamy V, et al. (2008). Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125:193–209.
   PubMed Web of Science ®Google Scholar
• Mura S, Hillaireau H, Nicolas J, et al. (2011). Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomed 6:2591–605.
   PubMed Web of Science ®Google Scholar
• Nichols JW, Bae YH. (2012). Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7:606–18.
   PubMed Web of Science ®Google Scholar
• Nierkens S, den Brok MH, Roelofsen T, et al. (2009). Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4:e8368.
   PubMed Web of Science ®Google Scholar
• Otto F, Schmid P, Mackensen A, et al. (1996). Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32:1712–8.
   Web of Science ®Google Scholar
• Paillard A, Hindré F, Vignes-Colombeix C, et al. (2010). The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 31:7542–54.
   PubMed Web of Science ®Google Scholar
• Petersen LK, Ramer-Tait AE, Broderick SE, et al. (2011). Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Sci Rep 1:6815–22.
   Google Scholar
• Rothstein JL, Schreiber H. (1988). Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci 85:607–11.
   PubMed Web of Science ®Google Scholar
• Roy A, Singh MS, Upadhyay P, et al. (2010). Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol Pharm 7:1778–88.
   PubMed Web of Science ®Google Scholar
• Satoh M, Ando S, Shinoda T, et al. (2008). Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. Innate Immunity 14: 51–60.
   PubMed Web of Science ®Google Scholar
• Sato K, Yoo YC, Fukushima A, et al. (1995). A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia. Infect Immun 63:2859–66.
   PubMed Web of Science ®Google Scholar
• Schromm AB, Brandenburg K, Loppnow H, et al. (1998). The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol 161:5464–71.
   PubMed Web of Science ®Google Scholar
• Shakya AK, Nandakumar KS. (2013). Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J R Soc Interface 10:20120536.
   PubMed Web of Science ®Google Scholar
• Stier S, Maletzki C, Klier U, et al. (2013). Combinations of TLR ligands: a promising approach in cancer immunotherapy. Clin Dev Immunol 2013:1–14. Article ID 271246.
   Google Scholar
• Su BB, Shi H, Wan J. (2012). Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 18:2121–6.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tanaka R. (1980). Carcinoembryonic antigen in patients with intracranial tumors. J Neurosurg 53:355–60.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, et al. (2012). Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:1557–907.
   PubMed Web of Science ®Google Scholar
• Vosika GJ, Barr C, Gilbertson D. (1984). Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 18:107–12.
   PubMed Web of Science ®Google Scholar
• Wiemann B, Starnes CO. (1994). Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharm Ther 64:529–64.
   PubMed Web of Science ®Google Scholar
• Zanoni I, Ostuni R, Marek LR, et al. (2011). CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 147:868–80.
   PubMed Web of Science ®Google Scholar